Providence St. Joseph Health

Providence St. Joseph Health Digital Commons
Journal Articles and Abstracts

1-31-2018

Complications of Subcutaneous Contraception: A
Review.
Rebecca C Ramdhan
Emily Simonds
Charlotte Wilson
Marios Loukas
Rod J Oskouian
Swedish Neuroscience Institute, Swedish Medical Center, Seattle, Washington, USA
See next page for additional authors

Follow this and additional works at: https://digitalcommons.psjhealth.org/publications
Part of the Obstetrics and Gynecology Commons
Recommended Citation
Ramdhan, Rebecca C; Simonds, Emily; Wilson, Charlotte; Loukas, Marios; Oskouian, Rod J; and Tubbs, R Shane, "Complications of
Subcutaneous Contraception: A Review." (2018). Journal Articles and Abstracts. 378.
https://digitalcommons.psjhealth.org/publications/378

This Article is brought to you for free and open access by Providence St. Joseph Health Digital Commons. It has been accepted for inclusion in Journal
Articles and Abstracts by an authorized administrator of Providence St. Joseph Health Digital Commons. For more information, please contact
digitalcommons@providence.org.

Authors

Rebecca C Ramdhan, Emily Simonds, Charlotte Wilson, Marios Loukas, Rod J Oskouian, and R Shane Tubbs

This article is available at Providence St. Joseph Health Digital Commons: https://digitalcommons.psjhealth.org/publications/378

Open Access Review
Article

DOI: 10.7759/cureus.2132

Complications of Subcutaneous
Contraception: A Review
Rebecca C. Ramdhan 1 , Emily Simonds 2 , Charlotte Wilson 2 , Marios Loukas 3 , Rod J. Oskouian
4 , R. Shane Tubbs 5
1. Department of Anatomical Sciences, St. George's University School of Medicine, Grenada, West Indies.
2. Seattle Science Foundation 3. Department of Anatomical Sciences, St. George's University School of
Medicine, Grenada, West Indies 4. Neurosurgery, Swedish Neuroscience Institute 5. Neurosurgery,
Seattle Science Foundation
 Corresponding author: Emily Simonds, easimonds@gmail.com
Disclosures can be found in Additional Information at the end of the article

Abstract
Over 62 million women in the United States are of childbearing age and 60% of them use
contraception. Subcutaneous contraceptives include implantable contraceptives and
subcutaneous injections. Implantable contraception involves subdermal time-release of
synthetic progestin, which allows for several years of continuous, highly effective
contraception. Its main effects are inhibition of ovulation and thickening of the cervical mucus.
Many complications have been associated with subcutaneous contraception, including
menstrual disturbances, headache, weight gain, acne, dizziness, mood disturbances, nausea,
lower abdominal pain, hair loss, loss of libido, pain at the implant site, neuropathy, and
follicular cysts. Using standard search engines, the complications of subcutaneous
contraception are reviewed. Patients should be adequately counseled on the possible
complications and side effects of subcutaneous contraception to help them make an informed
decision when choosing the right contraceptive to meet their needs.

Categories: Family/General Practice, Internal Medicine, Obstetrics/Gynecology
Keywords: subdermal, contraceptives, subcutaneous, neuropathy
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Contraception is defined as any method that prevents conception or childbirth. Numerous
medical options and devices can be used for this purpose. They can be classified as reversible
(behavioral, barrier, and hormonal) and permanent methods. Hormonal methods include oral
contraceptive pills, transdermal patches, vaginal rings, intrauterine devices, emergency
contraception, injectable contraception, and implantable contraceptives. This review focuses
on the medical complications of subcutaneous contraception, including injectable and
implantable contraceptives/subdermal methods.
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Review
Depot medroxyprogesterone acetate
Depot medroxyprogesterone acetate (DMPA), also called Depo-Provera, can be administered
intramuscularly (DMPA-IM) or via a subcutaneous injection (DMPA-SC). Medroxyprogesterone
acetate (MPA) is a derivative of progesterone, the active agent in this form of contraception.
The subcutaneous formulation contains 104 mg of the active drug, MPA, whereas the
intramuscular formulation contains 150 mg of MPA [1]. Like other forms of progestin-only

How to cite this article
Ramdhan R C, Simonds E, Wilson C, et al. (January 31, 2018) Complications of Subcutaneous
Contraception: A Review. Cureus 10(1): e2132. DOI 10.7759/cureus.2132

contraception, DMPA suppresses gonadotropin surges (luteinizing hormone and follicular
stimulating hormone), preventing follicular maturation. This also creates a physical barrier that
prevents sperm from entering the upper reproductive tract by increasing the viscosity of the
cervical mucus. The progestin-only contraceptive methods slow tubal and endometrial
mobility and make the lining of the endometrium much thinner than normal [2-3].
DMPA-SC effectively suppresses ovulation for at least 13 weeks in women. A report of two
multinational and multicenter contraceptive efficacy trials demonstrated no pregnancies
amongst 16,023 woman-cycles of exposure. These women represented a wide geographical
region (Asia, Europe, and North and South America) and a broad range of weights (77-364 lbs)
[4]. In contrast, DMPA-IM has a perfect-use failure rate of 0.3% and a typical-use failure rate of
3% in the first year [5].

Subdermal implants
Subdermal contraceptive implants have become popular contraceptive methods since they were
introduced in the United States in 1991. They are safe and effective in preventing pregnancy [6].
The implant contraception provides sustained slow release of the steroid progestin, which
results in anovulation, thinning of the endometrial lining, and thickening of the cervical
mucus, creating a barrier that is impenetrable to sperm [7].
Levonorgestrel-releasing Implants: There are two types of levonorgestrel (LNG)-releasing
implants, Norplant (Wyeth Ayerst Madison, NJ, USA) and Jadelle (Bayer, Turku, Finland). Both
are inserted subdermally under local anesthesia, usually in the inner region of the nondominant
arm. They release LNG continuously after insertion. Norplant is made up of six silastic capsules
and Jadelle consists of two silastic rods. The release rates for Norplant are 85, 50, and 30 µg/day
during the first, ninth, and 16th month of usage, respectively. At the 16th month, 69% of the
original steroid still remains in the capsules, which provides a safety margin for patients who do
not return on time to replace their contraceptive. The insertion and removal of Jadelle are
simpler because it has fewer units but achieves the same performance as Norplant. Sivin et al.
(1997) investigated both modalities over a three-year period and found that the serum LNG
levels in both systems were almost identical [8]. Levonorgestrel is very effective because of its
strong antiestrogenic properties. It inhibits ovulation, prevents normal sperm transport
through the female genital tract, and causes the inadequate development of the secretory
endometrium [9].
Implanon (Merck Whitehouse Station, NJ, USA): Implanon is a single implant with an easy
insertion and removal mechanism. The average serum level of etonogestrel with Implanon is
450 pg/ml, which decreases steadily to about 200 pg/ml at the end of three years [9]. It
effectively inhibits ovulation in nearly 100% of cycles in all women. Not a single pregnancy has
been reported in over 5,000 woman-years of exposure [10].
Nestorone (Zhejiang Xianju Pharmaceutical Co., Ltd. Xianju, Zhejiang, China): Nestorone is a
progesterone derivative, 16-methylene-17-alpha-acetoxy-19-norprogesterone. Nestorone is
inactive via the oral route, but with subcutaneous administration, it exerts a stronger
progestational activity than LNG or desogestrel and can be used for contraceptive purposes. It
lacks estrogenic, androgenic, and glucocorticoid activities [11].
According to Croxatto (2000), only one pregnancy was reported in roughly 4,000 womanmonths of exposure, which occurred in one of the lower dosage groups. A single Nestorone
implant that releases 150 µg/day can provide high contraceptive efficacy for two years with a
six-month margin safety. Because oral ingestion inactivates it, Nestorone allows for
satisfactory fertility regulation in breastfeeding mothers, as a transfer to the baby through
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breast milk will have no effect [10].
Uniplant: Uniplant, a progestin implant that releases nomegestrol acetate, was designed to be
effective for one year [11]. Benagiano et al. (2008) reported that the contraceptive effect of
Uniplant involves at least three different endocrine mechanisms: an inadequate luteal phase,
prevention of follicular growth, and development of a persistent non-luteinized follicle [11].

Medical complications
The medical complications associated with contraceptive implants include menstrual
disturbances, headache, weight gain, acne, dizziness, mood disturbances, nausea, lower
abdominal pain, hair loss, loss of libido, pain at the implant site, neuropathy, and follicular
cysts [12].
Menstrual Disturbances: In animal studies, normal menstruation occurs mainly from spiral
arterioles and is initially controlled by vasoconstriction [13]. In contrast, breakthrough bleeding
arises from small vessels on the endometrial surfaces, which consist of endothelial cells
surrounded by a basement membrane and pericytes. Evidence demonstrates that the integrity
of these small vessels is compromised by contraceptive implants [14]. During the initial
exposure to Norplant, the supporting structures around the vessels are reduced, making the
vessels more fragile, which explains the tendency of breakthrough bleeding during the first few
months. The progesterone-exposed endometrium has less vascular support from the pericytes
because the vascular smooth muscle is reduced [15]. Norplant also interacts with cytokeratin in
the endometrial epithelium, making the blood vessels more fragile, causing them to leak into
the endometrial cavity [16].
Several studies have investigated the relationship between bleeding patterns and ovarian
function, endometrial thickness and serum LNG levels. Women can experience a variety of
bleeding patterns despite similar hormonal levels. For example, low estradiol levels and an
absence of luteal activity can be associated with amenorrhea, frequent or prolonged bleeding
[17]. Those with regular bleeding patterns can have ultrasound images and estradiol and
progesterone levels compatible with normal ovulation, luteinized unruptured follicles,
persistent enlarged follies without ovulation, or even no follicular development [18-19].
In some studies, bleeding occurred after a rise and fall in serum estradiol or both estradiol and
progesterone. Prolonged bleeding was often concomitant with a drop in estradiol levels, ending
with a rise in estradiol levels [17]. In patients who had anovulatory cycles with Nestorone
implants, the bleeding period was significantly associated with the highest concentration of
estradiol during the previous 15 days [20].
Studies show that patients on Norplant have a thinner endometrium regardless of bleeding
patterns or hormonal levels (estradiol and progesterone) [21]. There is a positive association
between endometrial thickness, peripheral estradiol levels, and number of bleeding days
during the 90 days before endometrial biopsy [22]. Darney et al. found that a proliferative
endometrium was associated with abnormal bleeding in Norplant patients [23].
Vaginal bleeding pattern disturbances among Norplant users tend to be most common during
the first few months of use and are likely to diminish over time owing to a decrease in the rate
of LNG release, allowing ovulatory-like cycles to return [24]. According to Fraser et al., most
women experience prolonged bleeding at irregular intervals during the initial year, while 25%
have regular bleeding and approximately 10% have amenorrhea [25]. After the initial year, there
are decreases in the number of bleeding episodes and days and in the length of bleeding
periods; by the fifth year, 66% experience regular bleeding patterns, 33% experience irregular
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patterns, and amenorrhea is not common [26].
Implanon causes substantial vaginal bleeding irregularities, amenorrhea occurs in 30%-40% of
patients during the initial three months and subsequently remains around the same level. Half
of the users experience infrequent bleeding during the first three months but this decreases to
30% by the sixth month. Approximately 30% of patients had prolonged bleeding, which later
declined to less than 20% [14]. Implanon has been shown to cause more amenorrhea and less
frequent bleeding than Norplant does, whereas the incidence of prolonged bleeding is similar
in both methods and decreases with time [27].
Headache: According to Brache et al., headache seems to be the most common complaint
among patients using progestin implants [12]. There is wide variability among studies reporting
complaints of headaches, ranging between three percent and 69% of patients. The higher scores
were reported by Cullins et al.: 43%, Frank et al. : 49%, and Croxatto et al.: 69%. [28-30].
Headaches account for approximately 10%-20% of all medical reasons for the removal and
discontinuation of progestin implants, excluding menstrual disturbances. Less than five
percent of all users discontinue progestin implants because of headaches. The exact etiology is
unknown but is probably steroid-related [12].
Weight Changes: Weight gain is also a very common complaint among users. Every long-term
study focusing on any contraceptive method demonstrates an increase in the average weight of
users, but it is difficult to determine how much of that weight gain is related to the method of
contraception. Most studies exploring body weight have shown an average increase of 0.4-1.5
kg/year with all implant systems [12]. A controlled study by Sivin et al. reported a 0.7 kg/year
weight gain in both Norplant and intrauterine device (IUD) users, while another controlled
study found a 2.5 kg weight gain over five years in Chinese women [24]. However, the latter was
only 1.0 kg higher than the increase in nonhormonal controls according to the International
Collaborative Post-Marketing Surveillance of Norplant, 2001. Weight gain resulted in
the removal of implants in approximately 0.5%-5.6% of patients [12].
Weight loss was reported by 3.5% of users and was responsible for discontinuation rates of
0.2%-1.2% [12]. A small study noted a 0.8 kg weight loss after one year of Norplant use
compared to a 0.06 kg increase among DMPA users [31].
Acne, Hair Loss, and Hirsutism: Generally, acne, hair loss, and hirsutism are attributed to the
androgenic effects of progestogens and were found to be more common among Norplant
implants users than nonhormonal controls [12].
Acne has been reported in approximately 3%-27% of patients. More than half of the women
with pre-existing acne reported an improvement during usage, while the condition worsened in
about 10% [32].
Hair loss and hirsutism are not as common as acne. In two interview studies, 18%-19% of users
reported hair loss or abnormal hair growth during the first year of use. In a study comparing
Norplant with IUD users, patients more frequently experienced skin conditions (acne, hair loss,
and hirsutism) with Norplant (8.1% versus 3.2%) during the first year. However, in the second
year, this was reversed (7.9% versus 9.8%) [33]. The discontinuation rate due to acne ranged
from 0%-2% whereas the discontinuation rate due to hair loss and hirsutism ranged from 0%1% [12].
Dizziness: Reports indicate that 4%-11% of contraceptive implant users experience dizziness.
The rate of dizziness tends to be higher in Norplant users than nonhormonal controls [34].
According to Brache et al., the annual occurrence rate was higher during the first year than
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subsequent years of use (5%-8% versus 3%-4%) [12]. According to Coutinho, dizziness rarely
led to implant removal (0%-2.3%) [35].
Lower Abdominal Pain: Lower abdominal pain was apparent in 7%-23% percent of patients
using Norplant, Jadelle, and Implanon, with an annual occurrence rate of 7.3%-9.6% for
Norplant and Jadelle users. Less than 1.7% of women had their implants removed for this
indication [8,10].
Ovarian Cysts: Ovarian function is not fully suppressed by exposure to continuous low-dose
progestins, so gonadotropins are still released and dominant follicles develop. However, the
normal ovulatory process is disrupted so the follicle does not rupture, as it normally would. The
follicles become enlarged (>30 mm), and this gives the appearance of ovarian cysts, which
should spontaneously disappear in one to two months [36-37].
A number of studies in which the ovaries were examined sonographically demonstrated
persistent follicles in 56%-63% of cycles with the implant system, the maximum follicle
diameter being less than 35 mm [12]. According to Alvarez-Sanchez et al., one study
demonstrated that 17.6% of Norplant users but only 4% of IUD users had follicles with
diameters greater than 25 mm [37].
A persistent follicle found in implant users on ultrasound examination warrants a one-month
follow-up only. If it persists for more than two months, further studies are recommended, as it
could indicate a serious pathology [12].
Mood Disturbances: Women using implantable contraception are more likely to report mood
swings, nervousness, and depression than women using nonhormonal controls. With respect to
removal rates, mood changes accounted for 0%-1.7% whereas nervousness led to 0.2%-1.6%
and depression accounted for 0.2%-1.9% [12].
Nausea, Breast Tenderness, Loss of Libido, and Fatigue: Sivin reported that nausea affects
approximately 4%-12% of different implant users [24], a multicenter comparative study
showing 6.5% for Norplant and 3.8% for Implanon [32]. There was a higher annual rate during
the first year (7.5 per 100 woman-years) than subsequent years (4.2 per 100 woman-years) in
the US Norplant trial [38]. This differed from an international comparative study, which showed
an annual rate of 2.6 per 100 woman-years for Norplant users versus 2.9 per 100 woman-years
for Jadelle [8]. Removal rates for nausea were all less than 1.2% [12].
Breast tenderness has been reported in approximately 3%-16% percent of patients using
progestogen implants, with removal rates accounting for less than 1%. Loss of libido was
reported in approximately 2.0%-5.4% of implant users with removal rates between 0% and
0.8%. Fatigue has been reported in 2.5%-4.2% of Jadelle and Norplant users with removal rates
less than 0.6% [12].
Local Reactions: Pain localized at the insertion site is a common complication of subdermal
implants. It occurs in approximately 2% to 3% of all women and normally resolves by the third
month [39].
Infection has also been reported, with an incidence ranging from 0% to 1.4% [12]. Most
infections occur within the first two months after placement but some as late as two years after
[39]. A complication that can arise from infection is implant expulsion, but spontaneous
expulsion has also been reported in less than 0.6% of patients [12]. According to Klavon et al.,
35.7% of expulsions took place within the first two months after placement and about 70%
within the first four months [39].
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According to Sivin et al., 10.6% of patients reported changes in the color of their skin over the
implant site but this did not lead to discontinuation [40]. Another study reported that Jadelle
led to tenderness, numbness, tingling, and hyperpigmentation in more than 5% of patients [40].
Alvarez et al. reported that 36% of their patients experienced hyperpigmentation and 20% of
subjects experienced skin depression at the implant site [41]. The skin depression where the
tubes are implanted has the appearance of loss of subcutaneous fat in that area. This complaint
is more common among women with a larger body mass index (BMI), so it could be attributable
to their thicker layer of subcutaneous fat. Hyperpigmentation appears to be related to the
amount of melatonin in the skin. The exact etiology of these changes is unknown, but they
could be related to the local release of the steroid or could be a direct result of a reaction to a
foreign body [41].
Pregnancy: There have been over 200 reports of unintended pregnancies associated with
Implanon, which occurred during the first three years' post-marketing in Australia [42]. Out of
218 cases, 84 were attributed to noninsertion (documented evidence that the implant had not
been inserted, as it could not be located by palpation or ultrasound or there were negative
serum etonogestrel levels). Nineteen unintended pregnancies were due to incorrect timing
(Implanon was inserted outside the recommended times, i.e., not within the first five days of
the menstrual cycle or 21-28 days postpartum). Drug interaction accounted for eight cases.
Etonogestrel is normally metabolized by the CYP 3A4 enzyme, and in these eight cases, the
patients were taking hepatic enzyme-inducing antiepileptic drugs, which lowered the serum
etonogestrel levels. The Implanon was expelled in three cases, the product failed in 13 cases,
and there was insufficient information in 45. Lastly, and interestingly, 46 cases of unintended
pregnancies were due to prior conception, i.e. the dates of conception indicated that the patient
was already pregnant at the time of insertion [42].
Peripheral Neuropathy: Peripheral neuropathy is a rare complaint among women using
subdermal implants [28]. A case report by Hueston et al. discussed a 22-year-old woman who
presented with left arm paresthesias 11 months after receiving a subdermal implant on that
arm [43]. Internal rotation of her arms caused an electric shooting pain down the anterolateral
aspect of her left arm to her fingers, which was associated with numbness and paresthesias. The
pain lasted two to three minutes and could be reproduced by palpating the superior portion of
the axillary subdermal capsule. Physical examination showed a subdermal implant extending
from the mid-upper arm almost to the axilla, but there were no signs of inflammation
(erythema, tenderness, or induration) over any of the capsule paths. Nevertheless, compression
of the proximal portion of the most lateral subdermal capsule rekindled the symptoms [43].
In another case reported by Hueston et al., a 26-year-old woman presented with paresthesia
and numbness that radiated down the lateral aspect of her arm to her left hand. She stated that
one day previously, someone had grabbed her arm, causing immediate pain in the upper arm,
and the next day, she experienced the paresthesia and numbness, which were transient and
unrelated to arm movements. Compression of the site of trauma rekindled her symptoms. She
had had a subdermal contraceptive implant placed one year earlier in that arm. Physical
examination revealed no obvious sign of trauma but a subdermal implant was noted in the
mid-upper arm radiating toward the axilla. Palpation of the implant produced no localized pain
but palpation of the proximal tip of the capsule closest to the biceps muscle reproduced her
symptoms. It was found that she had acute nerve compression from a capsule and edema from
the soft tissue trauma. Her symptoms resolved with time [43].
Anatomically, the musculocutaneous nerve branches from the lateral cord of the brachial
plexus just distal to the axilla. It then travels posterior to the coracobrachial muscle, penetrates
the coracobrachialis, and extends to the anterior aspect of the arm. Symptoms are experienced
along the anterolateral aspect of the lower arm to the hand if this nerve is compressed. The two
case reports described above show a similar distribution of symptoms. In patients with short
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arms or in whom the subdermal capsule has been placed too proximally, the capsule’s tip can
exert pressure on the nerve where it penetrates the coracobrachial muscle, producing these
symptoms [43].
A case report by Marin et al. discussed a 27-year-old female who presented with numbness and
tingling along the medial arm, forearm, and ulnar hand associated with decreased left-handed
grip strength, and dexterity after her asymptomatic Norplant capsules had been removed
because she desired pregnancy. A physical examination demonstrated clinical findings
consistent with left ulnar nerve neuropathy and this was confirmed by nerve conduction
studies, which revealed absent left ulnar motor and sensory conduction potentials across the
Norplant removal site and scar. The patient underwent ulnar nerve epineurolysis, and a twomonth follow-up demonstrated no improvement in the motor and sensory clinical findings, but
she presented with the classic ‘claw hand’ indicative of advanced ulnar nerve palsy. After a sixmonth follow-up, there was only minimal, clinically insignificant, reinnervation of the ulnar
hand muscles [7].
Another case report of a 23-year-old nulliparous demonstrated ulnar nerve injury associated
with the removal of Norplant implants, which had been placed directly over the most anterior
region of the triceps brachii muscle, the lower end of the implant being approximately five cm
from the medial condyle of the elbow. The patient experienced a sharp, shooting pain down the
medial lower arm to the ulnar-innervated digits (fourth and fifth digits) as soon as the needle
was introduced. This pain was reproduced when another incision was made between the third
and fourth implants, but no notable nerve injury was found during exploration. When the
procedure was complete, the patient reported a mild, painful ‘tingly’ sensation but no weakness
or extreme pain. Four days after implant removal, she had persistent pain and numbness over
the hypothenar eminence along with the fourth and fifth digits and marked weakness of the
ulnar-innervated muscles on the right hand. Further tests led to a definite diagnosis of an ulnar
nerve injury [44]. After traumatic nerve injuries, motor function is initially reduced for three to
five days whereas sensory function is reduced for five to eight days. Improved motor response at
six weeks is a good prognostic sign for further recovery of ulnar nerve function [45].
Complications with implant insertions are rare, with an incidence of 0.3% [46]. Despite
anatomical variations, a general rule is that the neurovascular structures should be avoided
around the area of insertion, which is located below the deep fascia. The medial antebrachial
nerve (medial cutaneous nerve of the forearm) arises from the medial cord of the brachial
plexus, beginning between the axillary artery and the vein in the axilla, and provides sensory
innervation to the anteromedial region of the forearm. It descends medial to the brachial artery
and is closely associated with the basilic vein. The ulnar nerve descends posterior to the region
between the biceps and triceps, beneath the deep fascia. The medial cutaneous nerve emerges
through the deep fascia between the middle and lower arm and splits into anterior and
posterior branches to cross the elbow. Insertion of the implant into the subcutaneous tissue
about eight to 10 cm proximal to the medial epicondyle can help avoid injury to important
neurovascular structures [47].
According to Sivin et al., insertion site complications are a result of poor surgical technique
rather than Norplant capsules; 4.5%-7.5% of terminations of subdermal contraceptives are due
to complications that arise from implant placement [48]. Insertion errors include placing the
capsules either too superficially or too deeply. Placing the capsule in the dermis can lead to skin
blistering [49]. If capsules are placed too deeply or too far apart, multiple removal attempts may
be needed, which increases the risk of injury or infection [33].

Conclusions
It is important for physicians and patients to be educated about the side effects that can arise
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from the use of subcutaneous contraceptives. Additionally, it is important to weigh the risks
and benefits of each method. Physicians should be aware of the complications that can arise
when inserting subcutaneous contraceptive devices, though rare complications can occur.
Physicians should be familiar with the correct technique, including appropriate anatomical
placement and depth.
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